Nucleic Acid Therapeutics CDMO Market Research Report 2024-2034 Featuring Strategic Analysis of Lonza Group, Catalent, and Thermo Fisher Scientific Among Others [Yahoo! Finance]
Catalent, Inc. (CTLT)
Last catalent, inc. earnings: 2/3 07:30 am
Check Earnings Report
US:NYSE Investor Relations:
investor.catalent.com
Company Research
Source: Yahoo! Finance
The global nucleic acid therapeutics CDMO market accounted for USD 12.13 billion in 2023 and is expected to reach USD 32.78 billion by 2034 with a CAGR of 9.46% during the forecast period 2024-2034. The market will expand due to several factors, including rising demand for nucleic acid therapeutics, an increase in the prevalence of genetic and chronic diseases, an increase in FDA approvals of these drugs, a growing pipeline of nucleic acid therapeutics, and an increase in strategic alliances and partnerships. By type, the RNA-based therapies segment accounted for the highest revenue-grossing segment in the global nucleic acid therapeutics CDMO market in 2023 owing to the rapid adoption of mRNA vaccines and the expanding pipeline of RNA-based therapeutics for various diseases. For instance, the FDA approved the first gene therapy in June 2023 to cure particular Duchenne muscular dystrophy patients. Additionally, the gene therapy segment is predicted to grow at the fastest CAGR dur
Show less
Read more
Impact Snapshot
Event Time:
CTLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTLT alerts
High impacting Catalent, Inc. news events
Weekly update
A roundup of the hottest topics
CTLT
News
- Catalent, Inc. (NYSE: CTLT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Catalent, Inc. (NYSE: CTLT) had its price target raised by analysts at Barclays PLC from $47.00 to $63.00. They now have an "equal weight" rating on the stock.MarketBeat
- Sarepta cut to Neutral at Citi on risks to valuation [Seeking Alpha]Seeking Alpha
- Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies [Yahoo! Finance]Yahoo! Finance
- Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy [Seeking Alpha]Seeking Alpha
CTLT
Earnings
- 2/9/24 - Miss
CTLT
Sec Filings
- 6/5/24 - Form 4
- 6/4/24 - Form 144
- 5/29/24 - Form 8-K
- CTLT's page on the SEC website